0.10Open0.10Pre Close0 Volume3 Open Interest20.00Strike Price0.00Turnover0.00%IV73.28%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma116.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cybin Stock Discussion
EXCLUSIVE: Cybin Tells Benzinga Co. Announces Grant Of First U.S Composition of Matter Patent N Support Of Its CYB005 Phenethylamines Program
"Wait… did the DEA just tell us to double the supply of… drugs?! 😂 Looks like even the feds are bullish on psychedelics and THC. 🚀📈 Time to buy more $SNDL and invest in snack companies for the real winners! 🍕👀
loading...
4 mins ago
Cybin Inc: 12-Month Efficacy Data From Phase 2 Study of Cyb003 in Mdd Expected in Early Q4 2024
Cybin Inc -Phase 2 Topline Efficacy and Safety Results for Cyb004 in Generalized Anxiety Disorder ("Gad") Expected Year-End 2024 or Early Q1 2025
No comment yet